NCT02976675 is a Phase 4 clinical trial of PEG-somatropin in Growth Hormone Deficiency, sponsored by Changchun GeneScience Pharmaceutical Co., Ltd..

Who is sponsoring NCT02976675?

NCT02976675 is sponsored by Changchun GeneScience Pharmaceutical Co., Ltd..

What drugs are being tested in NCT02976675?

Interventions in NCT02976675: PEG-somatropin, PEG-somatropin.

What condition does NCT02976675 study?

NCT02976675 studies Growth Hormone Deficiency.

Is NCT02976675 still recruiting?

NCT02976675 is currently status unknown. Last updated 14 June 2017.

Last reviewed 2017-06-14 · How we verify

NCT02976675

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Pegylated Somatropin (PEG Somatropin) in the Treatment of Children With Growth Hormone Deficiency: A Multicenter, Randomized, Open-label, Parallel Phase IV Clinical Trial With Different Administration Frequency of PEG Somatropin

Status unknown Phase 4 Last updated 14 June 2017

What this trial tests

Phase 4 trial testing PEG-somatropin in Growth Hormone Deficiency in 600 participants. Status unknown.

Timeline

1 January 2015

Primary endpoint
1 June 2017

Quick facts

Lead sponsor	Changchun GeneScience Pharmaceutical Co., Ltd.
Phase	Phase 4
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	600
Start date	1 January 2015
Primary completion	1 June 2017
Sites	24 locations across China

Drugs / interventions tested

PEG-somatropin — full drug profile →
PEG-somatropin — full drug profile →

Conditions studied

Growth Hormone Deficiency — all drugs for Growth Hormone Deficiency →

Sponsor

Changchun GeneScience Pharmaceutical Co., Ltd. — full company profile →

Who can join

Adults 3 to 18, any sex, with Growth Hormone Deficiency. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Ht SDSca
Time frame: Baseline, 4,12,26 weeks after initiating treatment
Ht SDSca was calculated by dividing the difference between the actual height of a patient and the mean height of the population for that chronological age by the standard deviation (SD) of the height of the population for that chronological age

Sponsor's own description

To evaluate the safety and efficacy of PEG Somatropin Injection in the treatment of children with growth hormone deficiency, as well as to study the feasibility of extending the dosing intervals (once per two weeks) of PEG Somatropin Injection.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Long-acting growth hormone in the treatment of growth hormone deficiency in children: a systematic literature review and network meta-analysis.
Zhu J, Yuan K, Rana S, Jakki SL, et al · · 2024 · cited 14× · PMID 38580693 · DOI 10.1038/s41598-024-58616-4
Reduced Effectiveness and Comparable Safety in Biweekly <i>vs.</i> Weekly PEGylated Recombinant Human Growth Hormone for Children With Growth Hormone Deficiency: A Phase IV Non-Inferiority Threshold Targeted Trial.
Sun C, Lu B, Liu Y, Zhang Y, et al · · 2021 · cited 8× · PMID 34899612 · DOI 10.3389/fendo.2021.779365
Comparison between long-acting pegylated and daily recombinant human growth hormone for pediatric growth hormone deficiency a systematic review.
Zhang J, Guo S, Wang T, Chen Q. · · 2025 · cited 1× · PMID 40702077 · DOI 10.1038/s41598-025-10613-x

Verify or expand the search:

Other trials of PEG-somatropin

Trials testing the same drug.

NCT06024967 — A Study to Investigate the Safety and Efficacy of Once-weekly PEG-somatropin (GenSci004) in Children With Growth Hormone · Phase 3 · unknown

Other recruiting trials for Growth Hormone Deficiency

Currently open trials in the same condition.

NCT06542809 — Evaluation of the Propensity of Patients Under rhGH to Envision a Modification of Their Treatment Regimen Toward LAGH · NA · recruiting
NCT05681299 — Effects of GH and Lirglutide on AgRP · Phase 4 · recruiting
NCT06455956 — Use of miRNAs in Growth Hormone Deficiency (GHD) · recruiting

Other Changchun GeneScience Pharmaceutical Co., Ltd. trials

Trials by the same sponsor.

NCT07534176 — To Evaluate the Impact of Smoking on PK After Single-dose Oral Administration of GS1-144 Tablets . · Phase 1 · not yet recruiting
NCT07476586 — A Study to Evaluate the Safety, Tolerability, Pharmacokinetics of GenSci161 in Healthy Adult Participants · Phase 1 · not yet recruiting
NCT07491289 — GS1-144 in Participants With Hepatic Impairment and Healthy Female · Phase 1 · not yet recruiting
NCT07537231 — A Clinical Study to Evaluate the Absorption, Metabolism, and Excretion of Oral [14C]GS1-144 in Healthy Postmenopausal Fe · Phase 1 · not yet recruiting
NCT07366866 — A Study of Safety, Tolerability, PK, and PD of Subcutaneous GenSci136 in Healthy Adults. · Phase 1 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02976675 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Changchun GeneScience Pharmaceutical Co., Ltd.
Last refreshed: 14 June 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02976675.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing